Company:  SYNTHETIC BIOLOGICS, INC. (SYN)
Form Type:  8-K
Filing Date:  9/18/2020 
CIK:  0000894158 
Address:  9605 MEDICAL CENTER DRIVE
SUITE 270
 
City, State, Zip:  ROCKVILLE, Maryland 20850 
Telephone:  (734) 332-7800 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.36  
Change: 
0.051 (16.35%)  
Trade Time: 
Oct 23  
Market Cap: 
$7.06M
Trade SYN now with 

© 2020  
Description of Business
We are a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to treat gastrointestinal (GI) diseases in areas of high unmet need. Our lead clinical candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). We are also advancing SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
Register and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02. Departure of Directors or Certain Officers; ...
      Item 5.07. Submission of Matters to a Vote of Security Holders.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES